Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report)’s share price was down 4.7% during trading on Thursday . The stock traded as low as $4.83 and last traded at $4.84. Approximately 136,263 shares traded hands during trading, a decline of 48% from the average daily volume of 261,100 shares. The stock had previously closed at $5.08.
Aadi Bioscience Trading Down 5.1%
The company has a market cap of $114.10 million, a price-to-earnings ratio of -2.03 and a beta of 0.68. The stock has a 50 day moving average price of $4.26 and a two-hundred day moving average price of $3.96.
About Aadi Bioscience
Aadi Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genomically defined cancers. Headquartered in Redwood City, California, Aadi Bioscience was founded in 2012 and went public in 2019 on the Nasdaq Stock Market under the ticker AADI. The company’s research strategy centers on identifying molecular drivers of tumor growth and designing small-molecule inhibitors that target these pathways.
The company’s lead product candidate, fimepinostat (CUDC-907), is a novel dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K).
Featured Stories
- Five stocks we like better than Aadi Bioscience
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
- Amazon’s Zoox Push Tests Tesla’s Robotaxi Premium as Waymo Widens Its Lead
- MarketBeat Week in Review – 08/24 – 08/28
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
